Laura Gálvez-Melero: How a Combination of Imipramine and Ticlopidine Could Be a Promising Option for Glioma Treatment
Laura Gálvez-Melero, Phd Student at University of the Balearic Islands, shared a post on LinkedIn about an article by Ksenya Shchors, published in Cancer Cell, adding:
“Hiiii I’m back!
After taking a one-month break from sharing scientific content, I’m excited to return with more interesting papers and ideas, and of course my weekly questions!
Maybe some of you even missed it a little bit.
I think there isn’t a better way to come back than by sharing a research closely related to my thesis topic.
The study explores how a combination of Imipramine (a tricyclic antidepressant) and Ticlopidine (an anticoagulant) could be a promising option for glioma treatment.
And after this month, there’s an idea that concerns me…
We see a lot of science communication on social media every day, but what matters more nowadays: getting scientific information out quickly, or making sure it’s true”
Title: Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit
Authors: Ksenya Shchors, Aristea Massaras, Douglas Hanahan

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome
-
Nov 17, 2026, 13:37Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
-
Nov 17, 2026, 13:30Stacy E. Croteau: Oral and Dental Care in Pediatric Patients With Bleeding Disorders
-
Nov 17, 2026, 13:19Efe Saglam: Cannabis Use and Cardiac Conduction
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?